MIST Milestone Pharmaceuticals Inc.

CIK 0001408443 50 ready 8-Ks latest June 15, 2026, 4:05 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing June 15, 2026, 4:05 PM ET

Top materiality 0.90

Event mix other_material ×16 · earnings ×14 · regulatory ×11

Sentiment 21 pos · 3 neg · 26 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for MIST

Highest-materiality recent filing

Milestone receives FDA approval for CARDAMYST (etripamil) nasal spray for PSVT

December 15, 2025, 6:59 PM ET regulatory materiality 0.90 positive item 7.01 item 8.01 item 9.01

FDA approved CARDAMYST (etripamil) on Dec 12, 2025 for self-administration in adults with PSVT; first new treatment in 30+ years.
Phase 3 RAPID: 64% converted to sinus rhythm within 30 min vs 31% placebo (HR=2.62, p<0.001); median time 17 min vs 54 min.

Read filing →

June 15, 2026, 4:05 PM ET other materiality 0.30 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

Milestone Pharma shareholders approve 6.8M share increase to equity plan

Shareholders approved 2019 Equity Plan amendment to increase authorized shares by 6,800,000.
May 13, 2026, 7:23 AM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Milestone Q1 2026 net loss $26.1M; CARDAMYST launch yields $0.2M revenue, 600 scripts

Product revenue of $0.2M from first quarter of CARDAMYST launch; no prior-year revenue.
March 20, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Milestone Pharma FY2025 net loss $63.1M; CARDAMYST launch on track; cash runway into late 2027

Net loss of $63.1M ($0.75 per share) for FY2025 vs $41.5M ($0.67) prior year.
January 26, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Milestone launches CARDAMYST nasal spray for PSVT via U.S. retail pharmacies

CARDAMYST (etripamil) is now available through U.S. retail pharmacies as first self-administered PSVT treatment.
January 13, 2026, 6:59 PM ET other material materiality 0.70 positive item 8.01

Milestone closes $75M royalty sale to RTW for etripamil US net sales

Closed sale of royalty interest under Royalty Purchase Agreement with RTW Royalty I DAC.
January 6, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Milestone Pharma announces EMA acceptance of MAA for etripamil in PSVT; decision expected Q1 2027

EMA accepted Marketing Authorization Application for etripamil nasal spray (TACHYMIST) for PSVT; decision expected Q1 2027.
December 15, 2025, 6:59 PM ET regulatory materiality 0.90 positive item 7.01 item 8.01 item 9.01

Milestone receives FDA approval for CARDAMYST (etripamil) nasal spray for PSVT

FDA approved CARDAMYST (etripamil) on Dec 12, 2025 for self-administration in adults with PSVT; first new treatment in 30+ years.
November 12, 2025, 6:59 PM ET earnings materiality 0.85 neutral item 2.02 item 9.01

Milestone reports Q3 net loss $11.9M; PDUFA target Dec 13 for CARDAMYST in PSVT

Cash, equivalents and short-term investments $82.6M at Sept 30, up from $69.7M at Dec 31, 2024.
August 12, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Milestone Pharma: FDA accepts CRL response for CARDAMYST; new Dec 13 PDUFA date; Q2 net loss $13M

FDA accepted CRL response for CARDAMYST (etripamil) for PSVT; new PDUFA target Dec 13, 2025.
July 14, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01 item 8.01 item 9.01

Milestone Pharmaceuticals prices $52.5M public offering of common shares and warrants

Priced $52.5M offering of 31.5M common shares + Series A and B warrants at $1.50/unit; 3.5M pre-funded warrants at $1.499/unit.
July 11, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 1.01 item 8.01 item 9.01

FDA accepts Milestone's CRL response for CARDAMYST; new PDUFA Dec 13, 2025

FDA accepted Milestone's response to CRL for CARDAMYST (etripamil) nasal spray for PSVT; new PDUFA target date Dec 13, 2025.
June 16, 2025, 7:59 PM ET regulatory materiality 0.70 neutral item 8.01 item 9.01

Milestone submits CRL response for CARDAMYST (etripamil) PSVT NDA after Type A meeting

Submitted CRL response to FDA on June 16, 2025, following a productive Type A meeting.
June 12, 2025, 7:59 PM ET other material materiality 0.40 neutral item 5.02 item 5.07 item 9.01

Shareholders approve 2019 EIP amendment, increase share pool by 4M; directors elected

Proposal to amend 2019 EIP to remove evergreen provision and add 4,000,000 shares approved (8.04M for, 4.74M against, 14.9M broker non-votes).
May 14, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Milestone Pharma Q1 net loss $20.8M; CRL issues unresolved; Type A meeting requested

Q1 net loss $20.8M vs $10.4M YoY; no revenue; cash $56.0M down from $69.7M.
March 28, 2025, 7:59 PM ET regulatory materiality 0.90 negative item 8.01 item 9.01

FDA issues Complete Response Letter for etripamil PSVT NDA; no clinical issues raised

CRL focuses on CMC: additional nitrosamine impurity data and facility inspection required.
March 19, 2025, 7:59 PM ET other materiality 0.20 neutral item 5.08

Milestone Pharmaceuticals sets June 10, 2025 as annual meeting date; record date April 15

2025 annual meeting scheduled for June 10, 2025; record date for voting is April 15, 2025.
March 18, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01

Milestone Pharmaceuticals amends ATM sales agreement with Jefferies to up to $77.8M

Amended Open Market Sale Agreement replaces prior $50M facility; total capacity increased to $77.8M including ~$2.8M already sold.
March 13, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Milestone reports Q4 2024 net loss $12.4M; FDA PDUFA date for CARDAMYST is March 27, 2025

FDA PDUFA goal date for CARDAMYST (etripamil) in PSVT is March 27, 2025; launch targeted for mid-2025 if approved.
February 25, 2025, 6:59 PM ET regulatory materiality 0.75 neutral item 7.01 item 9.01

Milestone Pharma provides corporate presentation ahead of March 27 PDUFA for CARDAMYST

NDA for CARDAMYST (etripamil) nasal spray remains under FDA review with PDUFA date of March 27, 2025.
November 12, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Milestone reports Q3 net loss of $9.4M; PDUFA for CARDAMYST set for March 27, 2025

PDUFA target date for CARDAMYST (etripamil) in PSVT is March 27, 2025.
September 4, 2024, 7:59 PM ET leadership materiality 0.55 positive item 5.02 item 5.07 item 7.01 item 9.01 ◈ executive_change

Milestone Pharmaceuticals appoints Joseph Papa to Board of Directors

Joseph Papa, CEO of Emergent BioSolutions, appointed director effective Sept 3, 2024; over 35 years pharma experience.
August 8, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Milestone Q2 net loss $9.4M; FDA acceptance of CARDAMYST NDA with PDUFA March 2025

FDA accepted CARDAMYST (etripamil) NDA for PSVT; PDUFA target date set for March 2025.
July 15, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 5.02 item 5.08 item 8.01 item 9.01

Milestone adds two directors, plans third under agreement with Alta activist investor

Appointed Stuart Duty and Andrew Saik as independent directors effective July 14, 2024.
May 29, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Milestone Pharma gets FDA NDA acceptance for CARDAMYST (etripamil) nasal spray for PSVT

FDA accepted NDA on May 26, 2024 for CARDAMYST (etripamil) nasal spray for paroxysmal supraventricular tachycardia (PSVT).
May 13, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Milestone restarts PSVT NDA for etripamil; cash of $89.5M funds into 2026

NDA for etripamil in PSVT resubmitted after FDA Type A meeting; standard review expected, potential approval in H1 2025.
April 8, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Milestone Pharma reports positive Phase 3 etripamil data for PSVT self-treatment

NODE-303 open-label study: etripamil nasal spray restored sinus rhythm with median time-to-conversion 17.0 minutes.
March 28, 2024, 7:59 PM ET regulatory materiality 0.70 neutral item 8.01 item 9.01

Milestone Pharmaceuticals resubmits NDA for etripamil nasal spray to FDA for PSVT

NDA resubmission for self-administered etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT).
March 21, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Milestone Pharma reports Q4 net loss of $13.6M; on track to resubmit NDA for etripamil in PSVT early Q2 2024

Net loss of $13.6M in Q4 2023, full year net loss $59.7M; Q4 revenue was $0 (vs $3.5M in Q4 2022).
March 4, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Milestone Pharmaceuticals prices $30M public offering; net proceeds ~$32.4M

Offering of 16,666,667 common shares at $1.50/share and 3,333,333 pre-funded warrants at $1.499/warrant.
February 26, 2024, 6:59 PM ET regulatory materiality 0.80 neutral item 8.01 item 9.01

Milestone Pharma plans to resubmit NDA for etripamil in 2Q2024 after FDA Type A meeting

FDA indicated that timing of adverse events had minimal impact on overall etripamil safety profile.
December 26, 2023, 6:59 PM ET regulatory materiality 0.75 negative item 8.01 item 9.01

Milestone Pharma receives FDA refusal to file for etripamil NDA for PSVT

FDA issued Refusal to File letter for etripamil NDA submitted October 2023.
November 13, 2023, 6:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Milestone's etripamil Phase 2 meets primary endpoint; 30 bpm ventricular rate reduction vs placebo

Mean ventricular rate reduction of 29.91 bpm vs placebo (p<0.0001); absolute max reduction 35 bpm etripamil vs 5 bpm placebo.
November 13, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Milestone Pharma reports Q3 2023 results; NDA submitted for etripamil in PSVT

Cash $75.7M as of Sep 30, 2023; expected to fund operations into mid-2025.
November 7, 2023, 6:59 PM ET other material materiality 0.25 neutral item 7.01 item 9.01

Milestone to host webcast Nov 13 on etripamil Phase 2 AFib-RVR study results

Webcast on Monday Nov 13, 2023 at 8:00 a.m. ET to discuss ReVeRA Phase 2 results of etripamil in AFib-RVR.
October 24, 2023, 7:59 PM ET regulatory materiality 0.85 positive item 7.01 item 8.01 item 9.01

Milestone files NDA for etripamil; Phase 3 showed 2x efficacy, 3x speed vs placebo

Submitted NDA to FDA for etripamil (CARDAMYST) for paroxysmal supraventricular tachycardia (PSVT) on Oct 24, 2023.
August 10, 2023, 7:59 PM ET other material materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Milestone Pharma Q2 2023: cash $87.6M, NDA for etripamil due Oct 2023

Cash, equivalents & short-term investments of $87.6M; runway into mid-2025.
June 9, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 item 9.01 ◈ Shareholder Votes ×2

Milestone Pharmaceuticals holds 2023 annual meeting; all director nominees elected

All seven director nominees elected with substantial votes for; highest withheld was Robert J. Wills with 1,317,985 withheld.
May 11, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Milestone Pharma Q1 operating loss $15M; etripamil NDA on track for Q3 2023

Cash of $101M as of March 31, 2023; with $125M RTW financing, runway into mid-2025.
March 31, 2023, 7:59 PM ET debt materiality 0.75 positive item 2.03 item 3.02 item 7.01 item 9.01 ◈ Debt Financings ×2

Milestone Pharma raises $50M in convertible notes and $75M contingent royalty sale

Issued $50M principal of 6.0% Convertible Senior Notes due 2029 to RTW Investments.
March 29, 2023, 7:59 PM ET other material materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Milestone reports FY2022 operating loss of $58.4M; NDA for etripamil on track for Q3 2023

Cash, equivalents, and short-term investments of $64.6M as of Dec 31, 2022; plus $50M from March 2023 private placement expected to fund into mid-2025.
March 28, 2023, 7:59 PM ET debt materiality 0.80 positive item 1.01 item 7.01 item 9.01 ◈ Material Agreements ×2

Milestone Pharmaceuticals secures $125M financing from RTW for etripamil PSVT program

$50M in 6.0% convertible senior notes due 2029, convertible at $5.23/share (50% premium over VWAP).
March 27, 2023, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 3.02 item 5.02 item 9.01 ◈ executive_change◈ Material Agreements

Milestone exchanges 1.06M shares with RTW for pre-funded warrants; adds director Fischer

Exchanged 1,059,000 common shares with RTW Investments for pre-funded warrants at $0.001 exercise price, no expiration.
March 10, 2023, 6:59 PM ET other material materiality 0.60 positive item 7.01

Milestone Pharmaceuticals confirms no deposits or accounts at Silicon Valley Bank

Company states it does not hold any deposits or securities at Silicon Valley Bank.
March 7, 2023, 6:59 PM ET other materiality 0.20 neutral item 7.01 item 9.01

Milestone Pharmaceuticals provides updated corporate presentation at Cowen Healthcare Conference

Presentation filed as Exhibit 99.1; no financial figures or material updates disclosed in filing body.
December 6, 2022, 6:59 PM ET leadership materiality 0.80 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

CSO Francis Plat to retire Dec 31; company details etripamil commercial plan with NDA in mid-2023

CSO Francis Plat retires Dec 31, 2022; consulting agreement at $15k/month (Stage 1) or $300/hr (Stages 2/3).
November 10, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Milestone reports Q3 operating loss $14.6M; Phase 3 RAPID trial meets primary efficacy endpoint

Phase 3 RAPID trial met primary endpoint: 64.3% etripamil vs 31.2% placebo conversion to sinus rhythm within 30 min (HR=2.62, p<0.001).
October 17, 2022, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 9.01

Milestone Pharma announces positive Phase 3 RAPID trial results for etripamil in PSVT

Primary endpoint met: 64.3% of etripamil patients converted to sinus rhythm within 30 min vs 31.2% placebo (HR=2.62, p<0.001).
August 10, 2022, 7:59 PM ET other material materiality 0.70 positive item 2.02 item 9.01

Milestone Pharma: Phase 3 RAPID PSVT trial reaches 180 events; topline data on track for mid-H2 2022

Q2 2022 operating loss $16.8M vs income $0.7M prior year due to $15M one-time revenue from Ji Xing in 2021; cash $86.2M.
July 8, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

Milestone Pharmaceuticals shareholders elect directors, approve auditor and equity plan amendment at 2022 meeting

All six director nominees elected: Joseph Oliveto, Lisa M. Giles, Richard Pasternak, Debra K. Liebert, Michael Tomsicek, Robert J. Wills. Votes for each ranged 19,105,725 – 19,110,012.
March 24, 2022, 7:59 PM ET earnings materiality 0.55 neutral item 2.02 item 7.01 item 9.01

Milestone Pharma reports FY2021 net loss of $42.9M; revenue of $15M from collaboration

Net loss for FY2021 was $42.9M ($1.02 loss per share) vs $50.0M ($1.70 loss per share) in FY2020.

Executive changes

Appointed

Joeseph C. Papa

member of the Board

MIST · Milestone Pharmaceuticals Inc.

Effective: 2024-09-03
Filed: September 4, 2024, 7:59 PM ET

the Board of Directors (the “ Board ”) of Milestone Pharmaceuticals Inc. (the “ Company ”), upon the recommendation of the Nominating & Corporate Governance Committee of the Board, voted to elect Joeseph C. Papa as a member of the Board and as a member of the Board’s compensation committee (the “ Compensation Committee ”), effective as of September 3, 2024

Appointed

Seth H.Z. Fischer

Director

MIST · Milestone Pharmaceuticals Inc.

Effective: 2023-03-21
Filed: March 27, 2023, 7:59 PM ET

voted to elect Seth H.Z. Fischer to the Board, effective as of March 21, 2023

Departed

Francis Plat

Chief Scientific Officer

MIST · Milestone Pharmaceuticals Inc.

Effective: 2022-12-31
Filed: December 6, 2022, 6:59 PM ET

Mr. Oliveto, the Company’s Chief Executive Officer, announced Mr. Francis Plat’s intention to retire as Chief Scientific Officer from the Company, effective December 31, 2022.

Appointed

David Bharucha

Chief Medical Officer

MIST · Milestone Pharmaceuticals Inc.

Effective: 2022-02-15
Filed: February 16, 2022, 6:59 PM ET

Appointment of Chief Medical Officer On February 16, 2022, the Company announced the appointment of Dr. Bharucha as the Company’s Chief Medical Officer, effective February 15, 2022.

Earnings & guidance

2026-Q1 EPS reported -$0.20 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event other_material

21 positive 3 negative 26 neutral

source · MIST on sec.gov